Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
62
URGN Quote, Financials, Valuation and Earnings
Last price:
$15.40
Seasonality move
:
0.45%
Day range:
$14.33 - $15.50
52-week range:
$3.42 - $17.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.78x
P/B ratio:
16.41x
Volume:
2M
Avg. volume:
4.1M
1-year change:
-8.76%
Market cap:
$710.5M
Revenue:
$90.4M
EPS (TTM):
-$3.18
Analysts' Opinion
-
Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $34.38, UroGen Pharma has an estimated upside of 123.07% from its current price of $15.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing -3.83% downside risk from its current price of $15.41.
Fair Value
-
According to the consensus of 6 analysts, UroGen Pharma has 123.07% upside to fair value with a price target of $34.38 per share.
URGN vs. S&P 500
-
Over the past 5 trading days, UroGen Pharma has overperformed the S&P 500 by 4.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
UroGen Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
UroGen Pharma has grown year-over-year revenues for 16 quarters straight. In the most recent quarter UroGen Pharma reported revenues of $20.3M.
Earnings Growth
-
UroGen Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter UroGen Pharma reported earnings per share of -$0.92.
Enterprise value:
636.7M
EV / Invested capital:
--
Price / LTM sales:
7.78x
EV / EBIT:
--
EV / Revenue:
6.93x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.93x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$82.4M
Return On Assets:
-52.53%
Net Income Margin (TTM):
-150.68%
Return On Equity:
--
Return On Invested Capital:
-132.75%
Operating Margin:
-182.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $68M | $84.3M | $91.9M | $18.8M | $20.3M | |
| Gross Profit | $59.6M | $75.5M | $82.4M | $17.1M | $17.9M | |
| Operating Income | -$79.1M | -$69.2M | -$108M | -$25.7M | -$36.9M | |
| EBITDA | -$96.6M | -$85.1M | -$119.8M | -$29.4M | -$38.9M | |
| Diluted EPS | -$4.83 | -$3.24 | -$3.18 | -$0.87 | -$0.92 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $93.1M | $160.5M | $96M | $196.8M | $237.2M | |
| Total Assets | $97.4M | $165.7M | $113M | $200.6M | $247.6M | |
| Current Liabilities | $17M | $19.1M | $25.2M | $26.3M | $42M | |
| Total Liabilities | $20.9M | $182.8M | $229.5M | $240.7M | $294.1M | |
| Total Equity | $76.5M | -$17.1M | -$116.6M | -$40.1M | -$46.5M | |
| Total Debt | -- | $70.8M | $97.9M | $97.6M | $122.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$89.4M | -$82.3M | -$107.1M | -$31.7M | -$42M | |
| Cash From Investing | -$6.3M | $6.3M | -$60.1M | $13.5M | -$26M | |
| Cash From Financing | $27.1M | $170.9M | $140M | $54.7M | $34K | |
| Free Cash Flow | -$89.6M | -$82.5M | -$107.4M | -$31.7M | -$42.1M | |
URGN
Sector
Market Cap
$710.5M
$35.2M
Price % of 52-Week High
90.65%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
-19.85%
-1.01%
1-Year Price Total Return
-8.76%
-36.85%
Beta (5-Year)
1.017
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.34
200-day SMA
Buy
Level
$11.00
Bollinger Bands (100)
Buy
Level
7.61 - 13.21
Chaikin Money Flow
Buy
Level
2.6M
20-day SMA
Buy
Level
$13.97
Relative Strength Index (RSI14)
Buy
Level
68.18
ADX Line
Buy
Level
31.92
Williams %R
Sell
Level
-3.2491
50-day SMA
Buy
Level
$10.24
MACD (12, 26)
Buy
Level
4.05
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
6.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.0391)
Sell
CA Score
(Annual)
Level (-5.5075)
Buy
Beneish M-Score
(Annual)
Level (-2.9129)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.1927)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Stock Forecast FAQ
In the current month, URGN has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The URGN average analyst price target in the past 3 months is $34.38.
-
Where Will UroGen Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that UroGen Pharma share price will rise to $34.38 per share over the next 12 months.
-
What Do Analysts Say About UroGen Pharma?
Analysts are divided on their view about UroGen Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UroGen Pharma is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is UroGen Pharma's Price Target?
The price target for UroGen Pharma over the next 1-year time period is forecast to be $34.38 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is URGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for UroGen Pharma is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of URGN?
You can purchase shares of UroGen Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UroGen Pharma shares.
-
What Is The UroGen Pharma Share Price Today?
UroGen Pharma was last trading at $15.40 per share. This represents the most recent stock quote for UroGen Pharma. Yesterday, UroGen Pharma closed at $15.41 per share.
-
How To Buy UroGen Pharma Stock Online?
In order to purchase UroGen Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.83% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 13.12% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 5.29% over the past day.
